Table of Contents
Neopharmed Gentili told investors at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 that its European rare disease business, built on last year’s purchase of BioCryst’s European ORLADEYO operations, now has companies approaching it. Matteo Meazzini, who presented for business development alongside chief financial officer Bruno Sacchi, said the Milan-based company plans to keep adding products on a regular basis.
From Italy to Europe
Meazzini said the company now has more than 600 people across Europe and covers more than 10 therapeutic areas, including rare disease. Founded in Milan in 1972 as Mediolanum Farmaceutici, the group took its current form when Istituto Gentili and Neopharmed merged in 2011, according to the company. Private equity firm Ardian took a majority stake in 2018, and acquisitions since include MDM, Valeas, Bayer’s lormetazepam portfolio and, in 2025, the Italian rights to Sanofi’s gastroenterology brand Plasil.
In Italy, Meazzini said the company has more than 100 products and the second-largest sales force in the market, which Meazzini said makes the company think it is still “the partner of choice for anyone willing to launch commercially a product” there. When Meazzini joined about 10 years ago, cardiovascular medicines made up about 70% of the business, Meazzini said. “It was always our goal to, let’s say, differentiate and minimize the risks,” Meazzini said. The company reports cardiovascular at 39% of its specialty and primary care gross revenues in the first half of 2026.
The BioCryst deal and navenibart
Neopharmed Gentili bought all of BioCryst Ireland Limited, which held the European ORLADEYO (berotralstat) business for hereditary angioedema (HAE), for $250 million upfront plus up to $14 million in milestones, closing on October 1, 2025. Meazzini said the business is now fully integrated and that the company has a direct presence in 16 territories in Europe, with partners selling its products in about 50 countries.
In May 2026, an Irish affiliate of Neopharmed Gentili licensed European rights to navenibart, an investigational long-acting plasma kallikrein inhibitor for HAE, from BioCryst, which had acquired its developer, Astria Therapeutics. BioCryst expects topline results from the Phase 3 ALPHA-ORBIT trial in the third quarter of 2027, and BioCryst has said the program is on track for a US regulatory filing by the end of 2027. Meazzini said “we can leverage on the existing infrastructure”.
“And so our goal is really to make, let’s say, what we did for the Italian market, the same for the European ones,” Meazzini said.
Approaches from other companies
“We spent 2 years, you know, trying to find the right acquisition to start this European adventure. We think we found it,” Meazzini said. Now, Meazzini said, “companies are approaching us the other way around”, adding: “So we are continuously looking to have additional assets in the next years.”
The numbers
For the twelve months to June 2026, the company has reported total revenues of €361.6 million, adjusted EBITDA of €150.0 million, a 41.5% margin, and structuring adjusted EBITDA of €161.4 million, which adds run-rate BioCryst synergies, expected cost savings and a full-year contribution from acquired brands. Its first-half 2026 adjusted EBITDA margin was 39%, or 44% excluding rare disease.
Sacchi said the company is very cash generative, partly “since we don’t have any manufacturing activity internally”, and partly because of limited working capital needs. Neopharmed Gentili reports cash conversion of 103.8% for the twelve months to June 2026.
Competition and reimbursement
Asked about competition for rare disease assets, the company said “we think competition is everywhere”, but that it sees way less competition for some assets, where it hopes to act as “an aggregator of such products”. On reimbursement, the company said that for products with a clear value proposition for the patient, “we never saw any problem in obtaining reimbursement”.
About Neopharmed Gentili
Neopharmed Gentili is a privately held, Milan-based pharmaceutical company selling specialty and primary care medicines in Italy and rare disease medicines in Europe.
Onyx’s other coverage from this year’s conference includes GSK chair Sir Jonathan Symonds on pharma dealmaking and EyePoint.
Sources: Neopharmed Gentili company presentation, Jefferies Global Healthcare Conference, London, November 17, 2026; Neopharmed Gentili first half 2026 interim report and results presentation (August 28, 2026); Neopharmed Gentili and BioCryst announcements on the ORLADEYO Europe acquisition (June 27 and October 1, 2025) and the navenibart Europe licence (May 4, 2026); BioCryst second quarter 2026 results (August 5, 2026); Neopharmed Gentili company history
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments